A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
← catalyst calendarNCT07482657 · readout ≤ 134 d
Sponsored by Enanta Pharmaceuticals, Inc (industry) · ENTA — their whole pipeline →. With PENTA Foundation, AMS-PHPT Research Collaboration, Chiang Mai University.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
150estimated
Sites
8
Country
Thailand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-09 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- RSV Infection
- RSV
- Respiratory Syncytial Virus (RSV)
Interventions
- Drug: zelicapavir
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to complete resolution of clinical signs of RSV as measured by RESOLVE-P
measured Day 1 through Day 14
Permalink · ENTA's whole pipeline · Catalyst calendar · Every registered study · What changed